| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | |
|---|---|---|---|---|---|---|
Grant revenue | ||||||
- | - | - | 352 | 946 | 738 | |
Operating expenses: | ||||||
Research and development | ||||||
23,270 | 19,751 | 13,075 | 14,017 | 7,539 | 6,132 | |
General and administrative | ||||||
9,751 | 8,719 | 8,178 | 5,739 | 5,003 | 2,412 | |
Total operating expenses | ||||||
33,021 | 28,470 | 21,253 | 19,756 | 12,542 | 8,544 | |
Loss from operations | ||||||
-33,021 | -28,470 | -21,253 | -19,404 | -11,596 | -7,806 | |
Other income (expense): | ||||||
Interest income | ||||||
1,254 | 999 | 369 | 96 | 32 | - | |
Interest expense | ||||||
542 | - | - | - | - | - | |
Change in fair value of warrant liabilities | ||||||
-8,212 | -4,617 | 6,795 | -1,942 | - | - | |
Interest income | ||||||
- | - | - | - | - | 1 | |
Interest expense | ||||||
- | - | - | - | - | 1,907 | |
Net loss | ||||||
-24,097 | -22,854 | -27,679 | -17,366 | -11,564 | -9,712 | |
Unrealized gain/(loss) on marketable securities | ||||||
-230 | 18 | -16 | 11 | -18 | - | |
Comprehensive loss | ||||||
-24,327 | -22,836 | -27,695 | -17,355 | -11,582 | -9,712 | |
Net loss per common share: | ||||||
Basic | ||||||
-1.46 | -1.59 | -2.48 | - | - | - | |
Diluted | ||||||
-1.46 | -1.88 | -2.48 | - | - | - | |
Weighted-average number of shares outstanding: | ||||||
Basic | ||||||
16,454 | 14,372 | 11,153 | - | - | - | |
Diluted | ||||||
16,454 | 14,618 | 11,153 | - | - | - | |
Net loss per common share - basic and diluted | ||||||
- | - | - | -2.39 | -2.03 | -3.11 | |
Weighted-average number of shares outstanding - basic and diluted | ||||||
- | - | - | 7,256 | 5,682 | 3,118 | |